Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Low-Intensity Chemotherapy in Relapsed/Refractory ALL
NCT03808610Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2019
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2019; status: terminated.
02
Drugs
venetoclax
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03808610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808610.